The antitumor efficacy of RT reportedly relies on the IFN-stimulated pathway and cross-priming of tumor-associated DCs.11 Therefore, we evaluated the levels of antigen-specific DCs (CD45+/CD11c+/SIINFEKL+ cells) in TDLNs by flow cytometry. The gene discussed is PTPRC; the disease is neoplasm.